Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMT101 for Prevention of Hypertrophic Scar
NCT04012099Phase 2Terminated
- Sponsor
- Hugel
- Start
- Aug 2019
- Primary completion
- May 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of OLX10010 in Hypertrophic Scar (HS), sponsored by Hugel. Started Aug 2019; status: terminated.
02
Drugs
OLX10010
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT04012099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012099.